- Open Access
A novel APOC2 gene mutation identified in a Chinese patient with severe hypertriglyceridemia and recurrent pancreatitis
- Jingjing Jiang†1,
- Yuhui Wang†2,
- Yan Ling1,
- Abudurexiti Kayoumu2,
- George Liu2 and
- Xin Gao1Email author
© Jiang et al. 2016
- Received: 9 October 2015
- Accepted: 29 December 2015
- Published: 16 January 2016
The Erratum to this article has been published in Lipids in Health and Disease 2016 15:42
The severe forms of hypertriglyceridemia are usually caused by genetic defects. In this study, we described a Chinese female with severe hypertriglyceridemia caused by a novel homozygous mutation in the APOC2 gene.
Lipid profiles of the pedigree were studied in detail. LPL and HL activity were also measured. The coding regions of 5 candidate genes (namely LPL, APOC2, APOA5, LMF1, and GPIHBP1) were sequenced using genomic DNA from peripheral leucocytes. The ApoE gene was also genotyped.
Serum triglyceride level was extremely high in the proband, compared with other family members. Plasma LPL activity was also significantly reduced in the proband. Serum ApoCII was very low in the proband as well as in the heterozygous mutation carriers. A novel mutation (c.86A > CC) was identified on exon 3 of the APOC2 gene, which converted the Asp codon at position 29 into Ala, followed by a termination codon (TGA).
This study presented the first case of ApoCII deficiency in the Chinese population, with a novel mutation c.86A > CC in the APOC2 gene identified. Serum ApoCII protein might be a useful screening test for identifying mutation carriers.
- APOC2 gene
The severe forms of hypertriglyceridemia or chylomicronemia are usually caused by genetic defects. However, in most patients, it remains a challenge to define the underlying cause. The clinical features of chylomicronemia include: recurrent episodes of pancreatitis, hepatosplenomegaly, lipemia retinalis, and eruptive xanthomata. So far, mutations in five genes have been found responsible for a portion of these patients, namely lipoprotein lipase (LPL), apolipoprotein A-V (APOA5), apolipoprotein C-II (APOC2), glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) and lipase maturation factor 1 (LMF1) . Mutations in the LPL gene are the most common, while mutations in the APOC2 and LMF1 genes are rare.
The Apolipoprotein CII (ApoCII) protein circulates in the blood as a surface component of chylomicrons, VLDL, and HDL . It plays an important role in triglyceride metabolism as a cofactor for LPL, the rate limiting enzyme for hydrolysis and removal of triglycerides from chylomicrons and VLDL. ApoCII deficiency leading to chylomicronemia was first described in 1978 and was recognized as an autosomal recessive disease [3, 4]. Patients with ApoCII deficiency have marked alterations of triglyceride metabolism, leading to elevated fasting triglycerides, chylomicrons, and VLDL .
To our knowledge, mutation of the APOC2 gene has never been described in the Chinese population. Here we describe a novel homozygous mutation of the APOC2 gene, leading to truncation and loss of the entire C-terminal, in a Chinese female patient with severe hypertriglyceridemia and recurrent episodes of pancreatitis. The patient had a favorable response to orlistat treatment.
A 31-year old female was referred to our hospital due to persistent hypertriglyceridemia. Her mother recalled that once she was ill at 2 years old and at a local hospital, her blood was “white”. Later she recovered and didn’t follow up. At the age of 19, she experienced first episode of acute pancreatitis after a feast. During that episode, serum triglyceride level was unknown. Two years later, she was attacked by pancreatitis again during pregnancy and her serum triglyceride level was above the 22.5 mmol/L upper limit at a local hospital. She recovered later and gave birth to a healthy baby boy. After delivery she was treated with fibrates, niacins and statins, to which she responded poorly.
On admission, no eruptive cutaneous xanthomas or lipemia retinalis were found. Routine laboratory tests, with the exception of plasma lipids (see results), were within the reference range. Abdominal Computed Tomography (CT) scan revealed slight hepatosplenomegaly. Despite high level of TG, her liver fat accumulation was relatively mild, quantified as 11 % by liver Magnetic Resonance Spectroscopy (MRS). Her physical and mental development appeared normal. Her parents were consanguineous (cousins). Her younger sister and brother, as well as her 10-year old son all appeared normal, without history of dyslipidemia or pancreatitis.
Plasma lipid profile analysis
Blood samples were collected from the proband and her immediate family members after an overnight fast. Serum TG, T-C, HDL-C, LDL-C and non-HDL-C levels were measured enzymatically on an automatic analyzer (Hitachi High-Tech, 7600–120, Japan). The measurement of serum lipoproteins, including ApoAI(DiaSys, Germany), ApoB (DiaSys, Germany), ApoCII(Sekisui, Japan) and ApoE(Sekisui, Japan) was performed by immunoturbidimetric assays on an automatic analyzer (Hitachi High-Tech, 7600–120, Japan).
Postheparin plasma LPL activity assay
Postheparin plasma (10 min after iv injection of 50 IU/kg heparin) was collected and total lipase activity was determined by incubation of the plasma at 37 °C for 60 min with 3H-triolein emulsion substrate prepared as described previously , with or without heat-inactivated rat serum as source of exogenous ApoCII. Lipase activity was mainly for hepatic lipase (HL) activity after LPL activity was inhibited with 1 M NaCl on ice for 30 min. LPL activity was calculated by subtracting HL activity from total lipase activity (1 mU corresponds to 1 nmol free fatty acid generated per minute).
Analysis of candidate genes
Genomic DNA was extracted from peripheral blood leucocytes by a standard procedure. All exons, including the intron/exon boundaries of APOC2, LPL, LMF1, APOA5, and GPIHBP1 genes were PCR-amplified and sequenced as previously described . Genotyping of the APOE gene was also performed by TaqMan assays following manufacturer’s instructions.
The study was approved by the ethics committee of Zhongshan hospital, Fudan University. Informed consents were obtained from each subject participating in the study after full explanation of the purpose and nature of all procedures used.
Serum lipid and lipoproteins
Lipid profile of the pedigree
All the immediate family members of the proband had normal lipid levels, including TG, TC, HDL-C, LDL-C and non-HDL-C. All family members had lower level of ApoB, except the proband’s father, whose LDL-C was close to the upper limit. Interestingly, though detectable, the ApoCII level was low in all family members (Table 1).
The proband was maintained on strict low-fat diet and later was advised to take orlistat 60 mg tid. Though she didn’t strictly follow the suggested regimen, her TG declined gradually below 10 mmol/L and later further improved within 5 mmol/L during the past one year. In a recent follow up, serum TG level was 4.5 mmol/L (Table 1).
Postheparin plasma LPL activity
Post heparin plasma lipase activity (mU/ml)
without rat serum
with rat serum
Sequencing of candidate genes
A homozygous mutation on exon 3 of the APOC2 gene in the proband was identified: c.86A was replaced by 2 consecutive Cs(c.86A > CC), which converts the Asp codon at position 29 into Ala, followed by a termination codon (TGA) (Fig. 1d). The presence of this mutation was confirmed by sequencing at both directions. This mutation was not identified in 100 Chinese unrelated healthy controls, ruling out SNP. A heterozygous mutation was observed in the proband’s parents, her younger sister, brother and her son (Fig. 1e). Further subcloning and sequencing confirmed that they were all heterozygous mutation carriers. No mutation was identified on exons, as well as the intron/exon boundaries of LPL, LMF1, APOA5, and GPIHBP1 genes. The ApoE genotype of all family members, including the proband, was ε3/ε3.
Summary of APOC2 gene mutations
Amino acid change
c.-86A > G
c.1A > G
c.142 T > C
c.281 T > C
c.177C > G
c.177C > A
c.10C > T
c.255C > A
Loss of E2,3,4
IVS2 ds G-C +1
c.55 + 1G > C(ApoCII Hamburg)
c.86A > CC
The present mutation, which we designated ApoCIIShanghai, was predicted to translate into a truncated 29 amino acid peptide devoid of the C-terminal. The ApoCII level was very low in the proband’s serum possibly because either the protein itself was unstable and rapidly degraded, or the protein couldn’t be properly secreted. Similar ApoCII levels have been found in patients homozygous for other mutations (Table 3). Reports on the serum ApoCII protein levels of heterozygous relatives have been inconsistent. While ApoCIIToronto , ApoCIIWakayama , ApoCIIAuckland , ApoCIIhamburg  and the current ApoCIIShanghai heterozygous relatives had lower serum ApoCII levels, ApoCIIPadova heterozygotes had ApoCII levels similar to unaffected family members . Clinically, serum ApoCII levels are usually elevated in patients with hypertriglyceridemia. So low ApoCII combined with high TG levels might suggest ApoCII deficiency and the presence of low ApoCII levels in direct relatives even further increases this probability. In the present study, immunoturbidimetric assay was used to determine serum ApoCII levels. Although not as sensitive as radioimmunoassay, this method is less technically demanding and more applicable. It is also cost-effective and suitable for screening.
Paradoxically, both excess and deficiency of ApoCII are associated with hypertriglyceridemia. Transgenic mice overexpressing human ApoCII had marked hypertriglyceridemia and the ApoCII levels positively correlated with TG levels, due to impaired clearance and consequent accumulation of VLDL . Recently APOC2 loss-of-function mutant mice were generated using zinc finger nucleases, which exhibited high TG levels as expected . For patients with ApoCII deficiency, recurrent hyperlipidemic pancreatitis remains the major threat, while cardiovascular consequences are generally unremarkable. Due to uptake of chylomicrons by macrophages, hepatosplenomegaly is common, though fatty liver is actually mild, as in the present case.
Currently therapeutic interventions in ApoCII deficiency are still limited. Transfusion of normal plasma can provide temporarily sufficient ApoCII to activate LPL and normalize lipid profile . Though not applicable as a routine therapy, this is still of clinical significance, because in contrast to LPL deficiency, ApoCII deficient patients could benefit from fresh plasma transfusion in case of acute hyperlipidemic pancreatitis. Another ideal cure is a biologically active synthetic ApoCII peptide. According to one report, the reduction in plasma triglycerides after a single injection persisted for 13–20 days . Recently a novel bi-helical ApoCII mimetic peptide also showed promising effects in a mouse model . Unfortunately, due to the rarity of the disease, commercialized synthetic peptides are not available in the clinic. Impaired clearance of chylomicron is the major cause of hypertriglyceridemia in ApoCII deficiency. Orlistat, an agent for obesity, inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract to reduce the digestion and absorption of dietary fat, resulting in less intestinal chylomicron synthesis . A small study including 5 patients with type V hyperlipidemia showed the addition of orlistat to conventional therapy resulted in a further 35 % reduction in triglycerides . Interestingly, in the present case, orlistat markedly improved serum triglyceride compared with strict diet control alone. Though taken intermittently, orlistat brought the triglyceride level down to below 5 mmol/L and maintained well without rebound.
In conclusion, we identified a novel mutation in the APOC2 gene. This was also the first case of APOC2 gene mutation diagnosed in the Chinese population. In patients with severe hypertriglyceridemia, serum ApoCII might be a good screening marker for identifying mutation carriers. Orlistat might be effective and worth trying in homozygous patients, though synthetic ApoCII peptides are to be expected in future.
This work was supported by the National Natural Science Foundation of China (Grant No. 81270933), and the Major State Basic Research Development Program of China (2012CB524906 to X.G. We thank Shouxiong Huang (University of Cincinnati) for advice and suggestions on the manuscript.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Surendran RP, Visser ME, Heemelaar S, Wang J, Peter J, Defesche JC, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med. 2012;272:185–96.PubMed CentralView ArticlePubMedGoogle Scholar
- Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999;19:472–84.View ArticlePubMedGoogle Scholar
- Cox DW, Breckenridge WC, Little JA. Inheritance of apolipoprotein C-II deficiency with hypertriglyceridemia and pancreatitis. N Engl J Med. 1978;299:1421–4.View ArticlePubMedGoogle Scholar
- Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M. Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med. 1978;298:1265–73.View ArticlePubMedGoogle Scholar
- Ding Y, Wang Y, Zhu H, Fan J, Yu L, Liu G, et al. Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII. Transgenic Res. 2011;20:867–75.View ArticlePubMedGoogle Scholar
- Fojo SS, Law SW, Brewer Jr HB. Human apolipoprotein C-II: complete nucleic acid sequence of preapolipoprotein C-II. Proc Natl Acad Sci U S A. 1984;81:6354–7.PubMed CentralView ArticlePubMedGoogle Scholar
- Connelly PW, Maguire GF, Little JA. Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease. J Clin Invest. 1987;80:1597–606.PubMed CentralView ArticlePubMedGoogle Scholar
- Cox DW, Wills DE, Quan F, Ray PN. A deletion of one nucleotide results in functional deficiency of apolipoprotein CII (apo CII Toronto). J Med Genet. 1988;25:649–52.PubMed CentralView ArticlePubMedGoogle Scholar
- Crecchio C, Capurso A, Pepe G. Identification of the mutation responsible for a case of plasmatic apolipoprotein CII deficiency (Apo CII-Bari). Biochem Biophys Res Commun. 1990;168:1118–27.View ArticlePubMedGoogle Scholar
- Fojo SS, Beisiegel U, Beil U, Higuchi K, Bojanovski M, Gregg RE, et al. Donor splice site mutation in the apolipoprotein (Apo) C-II gene (Apo C-IIHamburg) of a patient with Apo C-II deficiency. J Clin Invest. 1988;82:1489–94.PubMed CentralView ArticlePubMedGoogle Scholar
- Fojo SS, de Gennes JL, Chapman J, Parrott C, Lohse P, Kwan SS, et al. An initiation codon mutation in the apoC-II gene (apoC-II Paris) of a patient with a deficiency of apolipoprotein C-II. J Biol Chem. 1989;264:20839–42.PubMedGoogle Scholar
- Fojo SS, Lohse P, Parrott C, Baggio G, Gabelli C, Thomas F, et al. A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency. J Clin Invest. 1989;84:1215–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Fojo SS, Stalenhoef AF, Marr K, Gregg RE, Ross RS, Brewer Jr HB. A deletion mutation in the ApoC-II gene (ApoC-II Nijmegen) of a patient with a deficiency of apolipoprotein C-II. J Biol Chem. 1988;263:17913–6.PubMedGoogle Scholar
- Inadera H, Hibino A, Kobayashi J, Kanzaki T, Shirai K, Yukawa S, et al. A missense mutation (Trp 26-->Arg) in exon 3 of the apolipoprotein CII gene in a patient with apolipoprotein CII deficiency (apo CII-Wakayama). Biochem Biophys Res Commun. 1993;193:1174–83.View ArticlePubMedGoogle Scholar
- Lam CW, Yuen YP, Cheng WF, Chan YW, Tong SF. Missense mutation Leu72Pro located on the carboxyl terminal amphipathic helix of apolipoprotein C-II causes familial chylomicronemia syndrome. Clin Chim Acta. 2006;364:256–9.View ArticlePubMedGoogle Scholar
- Okubo M, Toromanovic A, Ebara T, Murase T. Apolipoprotein C-II : a novel large deletion in APOC2 caused by Alu-Alu homologous recombination in an infant with apolipoprotein C-II deficiency. Clin Chim Acta. 2014;438C:148–53.Google Scholar
- Parrott CL, Alsayed N, Rebourcet R, Santamarina-Fojo S. ApoC-IIParis2: a premature termination mutation in the signal peptide of apoC-II resulting in the familial chylomicronemia syndrome. J Lipid Res. 1992;33:361–7.PubMedGoogle Scholar
- Streicher R, Geisel J, Weisshaar C, Avci H, Oette K, Muller-Wieland D, et al. A single nucleotide substitution in the promoter region of the apolipoprotein C-II gene identified in individuals with chylomicronemia. J Lipid Res. 1996;37:2599–607.PubMedGoogle Scholar
- Wilson CJ, Priore Oliva C, Maggi F, Catapano AL, Calandra S. Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy. Ann Neurol. 2003;53:807–10.View ArticlePubMedGoogle Scholar
- Xiong WJ, Li WH, Posner I, Yamamura T, Yamamoto A, Gotto Jr AM, et al. No severe bottleneck during human evolution: evidence from two apolipoprotein C-II deficiency alleles. Am J Hum Genet. 1991;48:383–9.PubMed CentralPubMedGoogle Scholar
- Beil FU, Fojo SS, Brewer Jr HB, Greten H, Beisiegel U. Apolipoprotein C-II deficiency syndrome due to apo C-IIHamburg: clinical and biochemical features and HphI restriction enzyme polymorphism. Eur J Clin Invest. 1992;22:88–95.View ArticlePubMedGoogle Scholar
- Gabelli C, Bilato C, Santamarina-Fojo S, Martini S, Brewer Jr HB, Crepaldi G, et al. Heterozygous apolipoprotein C-II deficiency: lipoprotein and apoprotein phenotype and RsaI restriction enzyme polymorphism in the Apo C-IIPadova kindred. Eur J Clin Invest. 1993;23:522–8.View ArticlePubMedGoogle Scholar
- Shachter NS, Hayek T, Leff T, Smith JD, Rosenberg DW, Walsh A, et al. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest. 1994;93:1683–90.PubMed CentralView ArticlePubMedGoogle Scholar
- Sakurai T, Sakurai A, Vaisman BL, Amar MJ, Liu C, Gordon SM, et al. Creation of ApoC-II mutant mice and correction of their Hypertriglyceridemia with an ApoC-II mimetic peptide. J Pharmacol Exp Ther. 2015.Google Scholar
- Baggio G, Manzato E, Gabelli C, Fellin R, Martini S, Enzi GB, et al. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J Clin Invest. 1986;77:520–7.PubMed CentralView ArticlePubMedGoogle Scholar
- Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000;20:270–9.View ArticlePubMedGoogle Scholar
- Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol. 2002;89:229–31.View ArticlePubMedGoogle Scholar